Fiche société
European Organisation for Research and Treatment of Cancer - EORTC
Traitements, essais et publications liés.
Traitements4programmes
Essais2liés
Publications7liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| BIBX 1382RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BIBX 1382 in treating patients who have solid tumors. | Cancer | Phase 1 | À vérifier | Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Switzerland, … | À vérifier |
| indisulamRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of E7070 in treating patients who have stage IV melanoma. | Cancer | Phase 2 | À vérifier | Austria, Belgium, France, Germany, Italy, Norway, Portugal, Switzerland, … | À vérifier |
| BIBX 1382RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BIBX 1382 in treating patients who have solid tumors. | Cancer | Phase 1 | À vérifier | Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Switzerland, United Kingdom | À vérifier |
| indisulamRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of E7070 in treating patients who have stage IV melanoma. | Cancer | Phase 2 | À vérifier | Austria, Belgium, France, Germany, Italy, Norway, Portugal, Switzerland, United Kingdom | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| indisulam | Cancer | Phase 2 | NCT00014625 | E7070 in Treating Patients With Stage IV Melanoma | COMPLETED |
| BIBX 1382 | Cancer | Phase 1 | NCT00003980 | BIBX 1382 in Treating Patients With Solid Tumors | SUSPENDED |
Publications
7| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| BIBX 1382 | EGFR signaling upregulates surface expression of the GluN2B-containing NMDA receptor and contributes to long-term potentiation in the hippocampus. | Neuroscience | ||
| indisulam | Assessing the Stability of Molecular Glues with Weighted Ensemble Simulations. | Journal of chemical theory and computation | ||
| indisulam | Targeting PRMT5 inhibitor-induced adaptation in pancreatic cancer with the RBM39 degrader indisulam. | Cancer research communications | ||
| indisulam | RNA-binding motif proteins as context-dependent regulators of tumor-immune crosstalk, genome stability, and therapeutic vulnerabilities in cancer. | Frontiers in immunology | ||
| indisulam | [Modality strategy in Eisai drug discovery: challenges toward next-generation therapeutics using proximity-inducing compound]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica | ||
| BIBX 1382 | AZD8055 enhances in vivo efficacy of afatinib in chordomas. | The Journal of pathology | ||
| BIBX 1382 | Integration of 101 machine learning algorithm combinations to unveil m6A/m1A/m5C/m7G-associated prognostic signature in colorectal cancer. | Scientific reports |